263 related articles for article (PubMed ID: 31374887)
1. Application of Dithiocarbamates as Potential New Antitrypanosomatids-Drugs: Approach Chemistry, Functional and Biological.
Oliveira JWF; Rocha HAO; de Medeiros WMTQ; Silva MS
Molecules; 2019 Aug; 24(15):. PubMed ID: 31374887
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Potential of Natural Products as Antiparasitic Agents for Neglected Tropical Diseases.
Orosco D; Mendoza AR; Meléndez CM
Curr Top Med Chem; 2024; 24(2):89-108. PubMed ID: 37842892
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs.
Branco Santos JC; de Melo JA; Maheshwari S; de Medeiros WMTQ; de Freitas Oliveira JW; Moreno CJ; Mario Amzel L; Gabelli SB; Sousa Silva M
Molecules; 2020 Jun; 25(11):. PubMed ID: 32503272
[TBL] [Abstract][Full Text] [Related]
4. Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases.
Ravera M; Moreno-Viguri E; Paucar R; Pérez-Silanes S; Gabano E
Eur J Med Chem; 2018 Jul; 155():459-482. PubMed ID: 29908440
[TBL] [Abstract][Full Text] [Related]
5. Metal Compounds in the Development of Antiparasitic Agents: Rational Design from Basic Chemistry to the Clinic.
Gambino D; Otero Á L
Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855114
[TBL] [Abstract][Full Text] [Related]
6. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.
Kourbeli V; Chontzopoulou E; Moschovou K; Pavlos D; Mavromoustakos T; Papanastasiou IP
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361781
[TBL] [Abstract][Full Text] [Related]
7. Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis.
Lepesheva GI; Waterman MR
Curr Top Med Chem; 2011; 11(16):2060-71. PubMed ID: 21619513
[TBL] [Abstract][Full Text] [Related]
8. Metallodrugs for the Treatment of Trypanosomatid Diseases: Recent Advances and New Insights.
Navarro M; Justo RMS; Delgado GYS; Visbal G
Curr Pharm Des; 2021; 27(15):1763-1789. PubMed ID: 33185155
[TBL] [Abstract][Full Text] [Related]
9. Parasite prolyl oligopeptidases and the challenge of designing chemotherapeuticals for Chagas disease, leishmaniasis and African trypanosomiasis.
Bastos IM; Motta FN; Grellier P; Santana JM
Curr Med Chem; 2013; 20(25):3103-15. PubMed ID: 23514419
[TBL] [Abstract][Full Text] [Related]
10. Parasitology. Drugs to combat tropical protozoan parasites.
Gelb MH; Hol WG
Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767
[No Abstract] [Full Text] [Related]
11. Antiparasitic therapy.
Kappagoda S; Singh U; Blackburn BG
Mayo Clin Proc; 2011 Jun; 86(6):561-83. PubMed ID: 21628620
[TBL] [Abstract][Full Text] [Related]
12. Thiol redox biology of trypanosomatids and potential targets for chemotherapy.
Leroux AE; Krauth-Siegel RL
Mol Biochem Parasitol; 2016; 206(1-2):67-74. PubMed ID: 26592324
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Khare S; Nagle AS; Biggart A; Lai YH; Liang F; Davis LC; Barnes SW; Mathison CJ; Myburgh E; Gao MY; Gillespie JR; Liu X; Tan JL; Stinson M; Rivera IC; Ballard J; Yeh V; Groessl T; Federe G; Koh HX; Venable JD; Bursulaya B; Shapiro M; Mishra PK; Spraggon G; Brock A; Mottram JC; Buckner FS; Rao SP; Wen BG; Walker JR; Tuntland T; Molteni V; Glynne RJ; Supek F
Nature; 2016 Sep; 537(7619):229-233. PubMed ID: 27501246
[TBL] [Abstract][Full Text] [Related]
14. The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives.
Castillo E; Dea-Ayuela MA; Bolás-Fernández F; Rangel M; González-Rosende ME
Curr Med Chem; 2010; 17(33):4027-51. PubMed ID: 20939823
[TBL] [Abstract][Full Text] [Related]
15. Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective.
González M; Cerecetto H
Expert Opin Ther Pat; 2011 May; 21(5):699-715. PubMed ID: 21428846
[TBL] [Abstract][Full Text] [Related]
16. Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease.
Future Med Chem; 2013 Oct; 5(15):1709-18. PubMed ID: 24144408
[TBL] [Abstract][Full Text] [Related]
17. Systematic study of 1,2,3-triazolyl sterols for the development of new drugs against parasitic Neglected Tropical Diseases.
Porta EOJ; Ballari MS; Carlucci R; Wilkinson S; Ma G; Tekwani BL; Labadie GR
Eur J Med Chem; 2023 Jun; 254():115378. PubMed ID: 37084599
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes.
Gilbert IH
Biochim Biophys Acta; 2002 Jul; 1587(2-3):249-57. PubMed ID: 12084467
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei.
Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M
Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349
[TBL] [Abstract][Full Text] [Related]
20. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies.
Espuelas S; Plano D; Nguewa P; Font M; Palop JA; Irache JM; Sanmartín C
Curr Med Chem; 2012; 19(25):4259-88. PubMed ID: 22834813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
